share_log

AbbVie | 10-Q: Q2 2024 Earnings Report

AbbVie | 10-Q: Q2 2024 Earnings Report

艾伯维公司 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/07 15:01

Moomoo AI 已提取核心信息

AbbVie reported Q2 2024 global net revenues of $14.5 billion, increasing 4.3% year-over-year, with operating earnings of $4.0 billion and diluted EPS of $0.77. The growth was primarily driven by Skyrizi and Rinvoq, which saw revenues surge 44.8% and 55.8% respectively, helping offset a 29.8% decline in Humira sales due to biosimilar competition.The company completed its acquisition of ImmunoGen for $9.8 billion in February 2024, strengthening its oncology portfolio with Elahere which contributed $128 million in Q2 revenues. AbbVie issued $15 billion in senior notes to finance the ImmunoGen and Cerevel Therapeutics acquisitions. The gross margin improved to 71% from 69% in Q2 2023, benefiting from lower amortization of intangibles.Research and development expenses increased 12% to $1.9 billion as AbbVie continued investing in its pipeline. The company maintained its quarterly dividend at $1.55 per share and repurchased 5 million shares for $959 million during H1 2024. The effective tax rate was 36% for Q2 2024, up from 22% in Q2 2023, primarily due to business development activities.
AbbVie reported Q2 2024 global net revenues of $14.5 billion, increasing 4.3% year-over-year, with operating earnings of $4.0 billion and diluted EPS of $0.77. The growth was primarily driven by Skyrizi and Rinvoq, which saw revenues surge 44.8% and 55.8% respectively, helping offset a 29.8% decline in Humira sales due to biosimilar competition.The company completed its acquisition of ImmunoGen for $9.8 billion in February 2024, strengthening its oncology portfolio with Elahere which contributed $128 million in Q2 revenues. AbbVie issued $15 billion in senior notes to finance the ImmunoGen and Cerevel Therapeutics acquisitions. The gross margin improved to 71% from 69% in Q2 2023, benefiting from lower amortization of intangibles.Research and development expenses increased 12% to $1.9 billion as AbbVie continued investing in its pipeline. The company maintained its quarterly dividend at $1.55 per share and repurchased 5 million shares for $959 million during H1 2024. The effective tax rate was 36% for Q2 2024, up from 22% in Q2 2023, primarily due to business development activities.
艾伯维公司报告了2024年第二季度全球净收入为145亿美金，同比增长4.3%，经营收益为40亿美金，摊薄后每股收益为0.77美金。增长主要受到Skyrizi和Rinvoq的推动，它们的收入分别激增44.8%和55.8%，帮助抵消了因生物类似药竞争导致的Humira销售下降29.8%。该公司于2024年2月完成了对ImmunoGen的98亿美金收购，加强了其肿瘤学产品组合，其中Elahere在第二季度贡献了12800万美金的收入。艾伯维公司发行了150亿美金的高级票据，以融资ImmunoGen和Cerevel Therapeutics的收购。毛利率从2023年第二季度的69%提高至71%，受益于...展开全部
艾伯维公司报告了2024年第二季度全球净收入为145亿美金，同比增长4.3%，经营收益为40亿美金，摊薄后每股收益为0.77美金。增长主要受到Skyrizi和Rinvoq的推动，它们的收入分别激增44.8%和55.8%，帮助抵消了因生物类似药竞争导致的Humira销售下降29.8%。该公司于2024年2月完成了对ImmunoGen的98亿美金收购，加强了其肿瘤学产品组合，其中Elahere在第二季度贡献了12800万美金的收入。艾伯维公司发行了150亿美金的高级票据，以融资ImmunoGen和Cerevel Therapeutics的收购。毛利率从2023年第二季度的69%提高至71%，受益于无形资产的摊销减少。研究和开发支出增加了12%，达到19亿美金，因为艾伯维公司继续投资于其产品管道。该公司将季度股息维持在每股1.55美金，并在2024年上半年以95900万美金回购了500万股。2024年第二季度的有效税率为36%，高于2023年第二季度的22%，主要由于业务发展活动。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    吉利德科学
    GILD
    -- 111.160
    阿玛琳
    AMRN
    -- 0.467
    诺华制药
    NVS
    -- 111.400
    强生
    JNJ
    -- 163.130
    赛诺菲安万特
    SNY
    -- 54.910
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点